Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced ...

Savara Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of 0.00% with a gross margin of -25.64%. The profit margin, also known as the ...

On Wednesday, Savara Inc (SVRA) stock saw a decline, ending the day at $3.65 which represents a decrease of $-0.13 or -3.44% from the prior close of $3.78. The stock opened at $3.77 and touched a low ...

H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Savara (SVRA – Research Report) today and set a price target of $10.00.

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the Savara Early Access ...

LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA), a biopharmaceutical company focused on rare respiratory diseases, is set to ...

September 24, 2024--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the appointment of ...

Delvin Mudigi, popularly known as Savara of the boy band Sauti Sol, has called out on fans quick to judge without understanding the whole picture. Speaking to YouTuber Eve Mungai, Savara told how ...

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Savara (SVRA – Research Report), with a price ...

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory ...

LANGHORNE, Pa., September 06, 2024--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of ...